1. Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors

3. Introduction/Overview

4. Intensive Therapy Reduces Diabetes Complications Rates

5. Variability in Time-Action Profile of Basal Insulins*

6. Intensive Insulin Therapy Is Limited by Hypoglycemia and Weight Gain

7. Rates of Glycemic Control in T1DM by Age Group

8. HbA1c Testing and Time-in-Range Outcome

9. Purpose of Adjunct Therapies in T1DM

10. Adjunct Therapies: Metformin

11. Pramlintide Meta-Analysis in T1DM: Adverse Events

12. ADJUNCT One Liraglutide + Insulin: Effect on HbA1c

13. T2DM Therapies for T1DM: SGLT Inhibitors

14. SGLT1/2 Inhibition

15. InTANDEM 2: Sotagliflozin in T1DM

16. Dapagliflozin DEPICT-1 and DEPICT-2: Study Design

17. DEPICT-1: Change in HbA1c Over 24 Weeks

18. DEPICT-2: Adjusted Mean Change in HbA1c

19. DEPICT-2: Time in Target Range

20. The EASE Clinical Development Program

21. EASE Trial: Efficacy Results

22. SGLT2 Inhibitors: Kidney Damage, Genital Infections, and Other AEs

23. Forest Plot: Events Suggestive of Genital Infections in Patients With T2DM Receiving SGLT2 Inhibitors

24. Safety Issues: EASE, InTANDEM

25. DKA Risk With SGLT2 Inhibitors

26. Managing the DKA Risk

27. Managing the DKA Risk (cont)

28. Managing the DKA Risk (cont)

29. STICH Protocol

30. Summary and Conclusions

31. Abbreviations

32. Abbreviations (cont)